Characteristics of idiosyncratic drug-induced liver injury in children: Results from the DILIN prospective study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 2, 2011, Pages 182-189

  Molleston, Jean P ^a   Fontana, Robert J ^b   Lopez, M James ^b   Kleiner, David E ^c   Gu, Jiezhun ^d   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

drug induced liver injury; hepatotoxicity; liver biopsy; Roussel Uclaf Causality Assessment Method

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMITRIPTYLINE; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; ATOMOXETINE; AUTOANTIBODY; AZITHROMYCIN; BILIRUBIN; CARBAMAZEPINE; DAUNORUBICIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUOXETINE; FOLIC ACID PLUS NICOTINAMIDE PLUS ZINC OXIDE; ISONIAZID; LAMOTRIGINE; LEVOFLOXACIN; METHYLDOPA; METHYLPHENIDATE; MINOCYCLINE; NICOTINAMIDE; OXACILLIN; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; SULFAMETHOXAZOLE; VALPROIC ACID; VINCRISTINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT INJURY; CHILD; CHOLESTASIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL DAMAGE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS;

ADOLESCENT; ANTI-INFECTIVE AGENTS; AUTOANTIBODIES; BILE DUCTS; CAUSALITY; CENTRAL NERVOUS SYSTEM AGENTS; CHILD; CHILD, PRESCHOOL; DRUG-INDUCED LIVER INJURY; DRUG-INDUCED LIVER INJURY, CHRONIC; FEMALE; HEPATITIS; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 79961205204     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31821d6cfd     Document Type: Article

References (39)

1. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9. (Pubitemid 43247143)
2. Squires RH Jr, Shneider BL, Bucuvalas J, et al. The first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-8.
3. Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148:831-4. (Pubitemid 43870084)
4. Mecarelli O, Pulitano P, Mingoia M, et al. Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (MARS). Epilepsia 2005;46:1687-9. (Pubitemid 44921947)
5. Goldstein NS, Bayati N, Silverman AL, et al. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000; 114:591-8.
6. Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother 2001;35:533-8. (Pubitemid 32428125)
7. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006;15:156-64.
8. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. Philadelphia, PA: John Wiley & Sons; 2002:149-74.
9. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-42.
10. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85. (Pubitemid 36910027)
11. Benedetti MS, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003;17:281-99. (Pubitemid 36774164)
12. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 2008;47:3-10.
13. Rumack BH, Peterson RG. Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics 1978;62:898-903. (Pubitemid 9009962)
14. Anderson GD. Children versus adults: pharmacokinetic and adverseeffect differences. Epilepsia 2002;43:53-9. (Pubitemid 34633697)
15. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Safety 2009;32:55-68.
16. Danan G, Benichon C. Causality assessment of adverse risks to drugs: a novel method based on the conclusions of international consensus meetings and applications to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30. (Pubitemid 23333873)
17. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009;29:364-72.
18. Kleiner DE, Chalasani NP, Conjeevaram HS, et al. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) Study. Gastroenterology 2007;132:A773.
19. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
20. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-31.
21. Giannattasio A, D'Ambrosi M, Volpicelli M, et al. Steroid therapy for a case of severe drug-induced cholestasis. Ann Pharmacother 2006; 40:1196-9. (Pubitemid 43886981)
22. Roberts EA, Spielberg SP, Goldbach M, et al. Phenobarbital hepatotoxicity in an 8 month old infant. J Hepatol 1990;10: 235-9. (Pubitemid 20089167)
23. Tsagaropoulo-Stinga H, Mataki-Emmanouilidou T, Karida-Kavalioti S, et al. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985;4:270-3. (Pubitemid 15093171)
24. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002;14:601-7.
25. Murray KF, Hadzic N, Wirth S, et al. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008;47:395-405.
26. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135: 1924-34.
27. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-21. (Pubitemid 41096639)
28. DeValle MB, Klinteberg AV, Alem N, et al. Drug induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-95. (Pubitemid 44427506)
29. Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. N Z Med J 1996;109:315-9.
30. Bjornsson E, Olsson R. Outcome and prognostic markers in severe druginduced liver disease. Hepatology 2005;42:481-9. (Pubitemid 41061102)
31. Bjornsson E. The natural history of drug-induced liver injury. Semin Liver Dis 2009;29:357-63.
32. Nanayakkara PGCJ, Lekamwasam S, Pratheepan GJ. A girl with complicated Stevens-Johnson syndrome following ciprofloxacin; a case report. Galle Med J 2010;15:33-5.
33. Bonkovsky HL, Agrawal S, Fontana RJ, et al. Immuno-allergic (I-a) manifestations of drug-induced liver injury (DILI) in the USA. Results from the prospective study of the DILI Network. Hepatology abstract S1590 presented at Digestive Diseases Week. 2009.
34. FDA drug safety communication: aseptic meningitis associated with use of Lamictal (lamotrigine). http.//www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm221847.htm Chicago; May 31-June 3, Published August 12, 2010. Accessed December 1, 2010.
35. Eliastim M, Holmes AW. Hepatitis, arthritis and lupus cell phenomena caused by methyldopa. Am J Dig Dis 1971;16:1014-8.
36. Homberg J-C, Abuaf N, Hemly-Khalil S, et al. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 1985;5:722-7. (Pubitemid 15236613)
37. Beaune PH, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997;26:37-42.
38. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 2009;29:383-92.
39. Lheureux PER, Penaloza A, Zahir S, et al. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Crit Care 2005;9:431-40. (Pubitemid 41498538)